Wed, Aug 14, 8:45 PM (153 days ago)
On August 13, 2024, Guardion Health Sciences, Inc. reported its financial results for Q2 and the first half of 2024. The company is currently navigating significant changes, including a Plan of Liquidation and Dissolution following the sale of its Viactiv business. This strategic move raises questions about the future of its ocular healthcare segment and the overall viability of its remaining operations. The announcement highlights ongoing uncertainties, including potential supply chain disruptions and economic conditions that could impact financial performance. The company remains classified as an emerging growth entity and is subject to Nasdaq's continued listing requirements. Investors are cautioned against placing undue reliance on forward-looking statements, as actual outcomes may vary significantly due to inherent risks and uncertainties. The financial results and further details are available in the press release filed as Exhibit 99.1.